Overview
A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
Status:
Completed
Completed
Trial end date:
2017-02-22
2017-02-22
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study was to evaluate the safety and clinical activity of long-term dosing with revusiran (ALN-TTRSC). Dosing has been discontinued; patients are being followed-up for safety.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Alnylam Pharmaceuticals
Criteria
Inclusion Criteria:- Subjects who previously received and tolerated revusiran (ALN-TTRSC) in the
ALN-TTRSC-002 study
- Adequate liver function
- Not Pregnant or nursing
Exclusion Criteria:
- Inadequate renal function
- Uncontrolled hypertension, ischemic heart disease or clinically significant cardiac
arrhythmia
- Untreated hypo- or hyperthyroidism
- Prior major organ transplant